Literature DB >> 16773199

NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review).

Zhiquan Zhang1, Basil Rigas.   

Abstract

Pancreatic cancer is the most deadly of all gastrointestinal malignancies with near zero five-year survival. This review summarizes our understanding of the potentially important role of inflammation in cancer in general and pancreatic cancer in particular. Nuclear factor kappaB (NF-kappaB), a mediator of inflammatory responses, plays a significant role in carcinogenesis and is now emerging as a link between inflammation and cancer. NF-kappaB is activated in over two thirds of human pancreatic cancers; participates in early events of pancreatic carcinogenesis through its interactions with signaling pathways; and suppression of its activation restores pancreatic cell kinetics, mainly normalizing the suppressed apoptosis of pancreatic cancer. NF-kappaB is an excellent target for chemoprevention and its modulation for pancreatic cancer prevention appears promising. The next few years will likely expand our understanding of NF-kappaB biology; solidify NF-kappaB's role as a major link between chronic inflammation and pancreatic carcinogenesis; and witness the development of NF-kappaB-based approaches to pancreatic cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773199

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  37 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.

Authors:  Xiang-Lin Tan; Kalyan K Bhattacharyya; Shamit K Dutta; William R Bamlet; Kari G Rabe; Enfeng Wang; Thomas C Smyrk; Ann L Oberg; Gloria M Petersen; Debabrata Mukhopadhyay
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

Review 3.  Deploying mouse models of pancreatic cancer for chemoprevention studies.

Authors:  Paul J Grippo; David A Tuveson
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-02

Review 4.  Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis.

Authors:  Navneet Momi; Sukhwinder Kaur; Moorthy P Ponnusamy; Sushil Kumar; Uwe A Wittel; Surinder K Batra
Journal:  Carcinogenesis       Date:  2012-05-23       Impact factor: 4.944

5.  Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo.

Authors:  Zhiquan Zhang; Liqun Huang; Wenping Zhao; Basil Rigas
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

Review 6.  [Medicinal prevention of gastrointestinal tumors: aspirin, Helicobacter and more?].

Authors:  J C Becker; W Domschke; T Pohle
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

7.  TLR3-mediated NF-{kappa}B signaling in human esophageal epithelial cells.

Authors:  Diana M Lim; Sneha Narasimhan; Carmen Z Michaylira; Mei-Lun Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-09-24       Impact factor: 4.052

8.  Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.

Authors:  Willie Wilson; Albert S Baldwin
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies.

Authors:  Dingying Zhou; Ioannis Papayannis; Gerardo G Mackenzie; Ninche Alston; Nengtai Ouyang; Liqun Huang; Ting Nie; Chi C Wong; Basil Rigas
Journal:  Carcinogenesis       Date:  2013-01-21       Impact factor: 4.944

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.